Skip to content
TrialScanner

NCT05375084

SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation

Phase 1TerminatedBBIOLeadBMYCollaborator

Registry record

Lead sponsor
Navire Pharma Inc., a BridgeBio company
Conditions
Non Small Cell Lung Cancer; Solid Tumor
Primary completion
Apr 12, 2024Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT05375084 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT05375084: SHP2 Inhibitor BBP-398 in... | TrialScanner